GS-5816

DRUG2 trials

Sponsors

Gilead Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions

Chronic Hepatitis C

Phase 1

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

CompletedNCT01817985

Gilead SciencesChronic Hepatitis C

Start: 2013-03-31End: 2013-08-31Updated: 2013-08-29

Phase 2

Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816

CompletedNCT02468648

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Chronic Hepatitis C

Start: 2015-06-09End: 2018-09-14Updated: 2020-03-19